A human ex vivo model of radiation-induced skin injury recapitulates p53-driven profibrotic response to radiotherapy
JCI Insight · 2026
DOI: 10.1172/jci.insight.198692 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Caroline Dodson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Skin, Radiation Injuries, Radiotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIDDK NIH HHS, US National Institutes of Health.
Abstract (Originalsprache)
Cutaneous radiation injury is an unintended consequence of radiotherapy for many common cancers and can progress to debilitating radiation-induced skin fibrosis (RISF). Existing radiation injury models do not fully capture the skin toxicities observed in patients, contributing to the lack of efficacious therapies to mitigate RISF. To address this, we developed an ex vivo human skin model that recapitulates the temporal radiation injury and RISF response. Human skin explants ( n = 12) subjected to ionizing radiation demonstrated DNA double-stranded breaks and robust p53-driven transcriptional programming of cell cycle arrest, apoptosis, and senescence compared with nonirradiated controls. Irradiated skin also exhibited induction of pro-inflammatory cytokines, epithelial-mesenchymal transition, profibrotic TGF-β1–mediated signaling, and thickened collagen over time. P53 regulators murine double minute 2 (MDM2) and miR-34a were induced after irradiation and may be leveraged to modulate injury response. Notably, RNA-sequencing of postradiotherapy breast skin from patients who had undergone mastectomy showed similar p53, inflammatory, and TGF-β1 signatures as the ex vivo model, supporting its translational relevance. Together, this model provides a platform for identifying biomarkers and testing therapies to prevent or mitigate cutaneous radiation toxicities. Targeting the dynamic p53-driven profibrotic radiation response represents a potentially new therapeutic avenue to improve quality of life for patients after radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery.
- The Dr. John T Macdonald Foundation Department of Human Genetics, and.
- Dewitt Daughtry Family Department of Surgery, Division of Plastic, Aesthetic, and Reconstructive Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Förderung
- NIAMS NIH HHS
- NIDDK NIH HHS
- US National Institutes of Health
- Dermatology Foundation
Zitieren
APA
Dodson, C., Bilik, S. M., DiBartolomeo, G., Pachalis, H., Siegfried, L. G., Johnson, J. A., Thaller, S. R., Pastar, I., Tomic-Canic, M., Griswold, A. J., & Stone, R. C. (2026). A human ex vivo model of radiation-induced skin injury recapitulates p53-driven profibrotic response to radiotherapy. JCI Insight. https://doi.org/10.1172/jci.insight.198692
Vancouver
Dodson C, Bilik SM, DiBartolomeo G, Pachalis H, Siegfried LG, Johnson JA, et al. A human ex vivo model of radiation-induced skin injury recapitulates p53-driven profibrotic response to radiotherapy. JCI Insight. 2026. doi:10.1172/jci.insight.198692
BibTeX
@article{Dodson2026,
author = {Dodson, Caroline and Bilik, Sophie M and DiBartolomeo, Gabrielle and Pachalis, Hannah and Siegfried, Lindsey G and Johnson, Jordan Ak and Thaller, Seth R and Pastar, Irena and Tomic-Canic, Marjana and Griswold, Anthony J and Stone, Rivka C},
title = {A human ex vivo model of radiation-induced skin injury recapitulates p53-driven profibrotic response to radiotherapy},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.198692}
}
EUVIMED